DRMA — Dermata Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1853816 ·
Last close
$1.12
Market Cap
$5.55M
52W High
$5.87
52W Low
$0.95
ADV30
73,308
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,013,567 | -2,967,063 | 5,320,799 | 4,412,764 | 1,833,079 |
| Mar 2026 | 0 | — | -1,926,382 | -1,847,706 | 7,465,652 | 6,945,282 | — |
| Dec 2025 | 0 | — | -1,900,393 | -1,861,888 | 7,863,826 | 7,521,978 | 1,640,446 |
| Sep 2025 | 0 | — | -1,760,671 | -1,691,989 | 5,071,410 | 4,664,127 | 1,111,308 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,303,211
Investing CF
—
Financing CF
$5,529,225
CapEx
—
Dividends Paid
—
Buybacks
$-367
EPS Diluted TTM
$-8.26
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-75,081,602
Inventory
$93,091
Receivables
—
ST Investments
—
EBIT TTM
$-7,360,177
Pretax Income TTM
$-7,102,676
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,773,598 | -7,558,557 | 7,863,826 | 1,640,446 | 6,223,380 | -7,757,559 |
| Dec 2024 | 0 | -12,513,242 | -12,287,461 | 3,533,888 | 1,972,794 | 1,561,094 | -11,162,948 |
| Dec 2023 | 0 | -8,041,906 | -7,794,690 | 7,978,634 | 1,623,616 | 6,355,018 | -6,408,931 |
| Dec 2022 | 0 | -9,674,486 | -9,610,913 | 6,944,488 | 922,634 | 6,021,854 | -8,834,164 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.87
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XTLB | XTL BIOPHARMACEUTICALS LTD | $5.48M | $2.23 | — |
| XBIO | Xenetic Biosciences, Inc. | $5.46M | $2.33 | — |
| KAPA | Kairos Pharma, LTD. | $5.69M | $1.68 | — |
| NCNA | NuCana plc | $5.37M | $1.29 | — |
| ACXP | Acurx Pharmaceuticals, Inc. | $5.76M | $1.34 | — |
News headlines (Yahoo Finance, 1h cache)
Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Labor
2026-08-31 09:05 · Yahoo
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
2026-08-25 12:30 · Yahoo
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
2026-08-21 12:30 · Yahoo
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
2026-08-11 20:05 · Yahoo
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
2026-08-05 12:30 · Yahoo
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
2026-05-13 20:05 · Yahoo
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
2026-04-02 12:30 · Yahoo
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2026-08-17 12:30 · Yahoo
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
2026-03-26 21:15 · Yahoo
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
2026-03-10 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.